Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: EXPAREL

« Back to Dashboard
Exparel is a drug marketed by Pacira Pharms Inc and is included in one NDA. It is available from one supplier. There are two patents protecting this drug.

This drug has twenty patent family members in fifteen countries.

The generic ingredient in EXPAREL is bupivacaine. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the bupivacaine profile page.

Summary for Tradename: EXPAREL

Suppliers / Packagers: see list1

Pharmacology for Tradename: EXPAREL

Drug ClassAmide Local Anesthetic
Physiological EffectLocal Anesthesia

Clinical Trials for: EXPAREL

EXPAREL Infiltrated Into the TAP for Postoperative Analgesia in Unilateral Abdominal Hernia Repair
Status: Completed Condition: Hernia

EXPAREL Administered Into the TAP for Analgesia in Subjects Undergoing Open Total Abdominal Hysterectomy
Status: Terminated Condition: Postoperative Pain

Pharmacokinetic Evaluation of EXPAREL in Adults Undergoing Tonsillectomy
Status: Completed Condition: Pain

EXPAREL Administered by Infiltration Into the TAP for Prolonged Postsurgical Analgesia in Lower Abdominal Surgeries
Status: Terminated Condition: Postsurgical Analgesia

TAP-patients With Robotic Assisted Lap Prostatectomy
Status: Completed Condition: Postsurgical Pain; Analgesia; Prostatectomy

Peri-articular Injection Utilizing a Pain Cocktail With and Without Exparel
Status: Not yet recruiting Condition: Total Knee Arthroplasty; Pain Management

Evaluation of the Safety and Efficacy of EXPAREL When Administered Into the TAP in Subjects Undergoing Cesarean Section
Status: Terminated Condition: Pain

EXPAREL Infiltration in Subjects Undergoing Femoral Nerve Block With Bupivacaine HCl for Total Knee Arthroplasty
Status: Completed Condition: Pain

Pain Management in Response to Exparel vs. Standard Bupivicaine
Status: Recruiting Condition: Pain

Pharmacokinetics and Safety of Bupivacaine HCl Spinal Block and EXPAREL Local Infiltration in Total Knee Arthroplasty
Status: Completed Condition: Pain

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pacira Pharms Inc
INJECTABLE, LIPOSOMAL;INJECTION022496-001Oct 28, 2011DISCNNo8,182,835<disabled>Y <disabled>
Pacira Pharms Inc
INJECTABLE, LIPOSOMAL;INJECTION022496-002Oct 28, 2011RXYes8,182,835<disabled>Y <disabled>
Pacira Pharms Inc
INJECTABLE, LIPOSOMAL;INJECTION022496-001Oct 28, 2011DISCNNo8,834,921<disabled>Y <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: EXPAREL

Country Document Number Publication Date
European Patent Office1014946Jul 05, 2000
Cyprus1110135Jan 14, 2015
Portugal1014946Jul 06, 2010
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn